Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data

BACKGROUND: Refractory and relapsed multiple myeloma (RRMM) remains a clinical challenge. We compared the progression-free survival (PFS) of RRMM patients treated with lenalidomide and low dose dexamethasone plus elotuzumab or carfilzomib (ELD vs. CLD), using reconstructed individual patient data (I...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shuo, Meng, Xiang-Yu, Maman, Souraka Tapara Dramani, Xiao, Yong-Nong, Li, Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311249/
https://www.ncbi.nlm.nih.gov/pubmed/30643823
http://dx.doi.org/10.1155/2018/9057823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311249/
https://www.ncbi.nlm.nih.gov/pubmed/30643823
http://dx.doi.org/10.1155/2018/9057823

Ejemplares similares